华熙生物2月2日获融资买入6800.48万元，融资余额5.50亿元

Group 1 - On February 2, Huaxi Bio's stock rose by 5.24%, with a trading volume of 562 million yuan [1] - The financing data shows that on the same day, Huaxi Bio had a financing purchase amount of 68.0048 million yuan and a net financing purchase of 3.4537 million yuan [1] - As of February 2, the total balance of margin trading for Huaxi Bio was 554 million yuan, with a financing balance of 550 million yuan, accounting for 2.42% of the circulating market value [1] Group 2 - Huaxi Bio, established on January 3, 2000, and listed on November 6, 2019, operates in the field of microbial fermentation and cross-linking technology, focusing on bioactive materials for health [2] - The company's revenue composition includes 40.34% from skin science innovation, 29.76% from medical terminal products, and 27.70% from raw materials [2] - For the period from January to September 2025, Huaxi Bio reported a revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit of 252 million yuan, down 30.29% year-on-year [2] Group 3 - Since its A-share listing, Huaxi Bio has distributed a total of 1.138 billion yuan in dividends, with 528 million yuan distributed in the last three years [3] - As of September 30, 2025, major shareholders of Huaxi Bio have seen a reduction in holdings, with the top ten circulating shareholders decreasing their shares [3]